Literature DB >> 27222868

Effect of osmolytes on the conformation and aggregation of some amyloid peptides: CD spectroscopic data.

Mohammed Inayathullah1, Jayakumar Rajadas2.   

Abstract

Protein misfolding and aggregation are responsible for a large number of diseases called protein conformational diseases or disorders that include Alzheimer׳s disease, Huntington׳s diseases, Prion related encephalopathies and type-II diabetes (http://dx.doi.org/10.1038/35041139) (Kopito and Ron, 2000) [1]. A variety of studies have shown that some small organic molecules, known as osmolytes have the ability to stabilize native conformation of proteins and prevent misfolding and aggregation (http://www.la-press.com/article.php?article_id=447) (Zhao et al., 2008) [2]. It has been shown that certain short segment or fragment of respective proteins can also form amyloids, and the segments also promote the aggregation in the full-length protein (http://dx.doi.org/10.2174/0929867023369187) (Gazit, 2002) [3]. This article presents circular dichroism spectroscopic data on conformational analysis and effect of osmolytes on Aβ peptide fragments, different lengths of polyglutamine peptide and the amyloidogenic segment of islet amyloid polypeptide.

Entities:  

Keywords:  Aggregation; Amyloid β-protein; Circular dichroism; Conformation; Islet amyloid polypeptide; Osmolytes; Peptides; Polyglutamine

Year:  2016        PMID: 27222868      PMCID: PMC4872718          DOI: 10.1016/j.dib.2016.04.070

Source DB:  PubMed          Journal:  Data Brief        ISSN: 2352-3409


Specifications Table Value of the data Circular dichroism (CD) and infrared (IR) spectroscopic data of peptide fragments of amyloid β-protein (Aβ), poly-glutamine (polyQ) and islet amyloid polypeptide (IAPP) provides the secondary structure information in their self-assembled and/or aggregated states. This data is useful in understand conformational dynamics of the smaller peptide analogs of the full length amyloid proteins/peptides. Time-dependent CD data provide information on the aggregation kinetics and conformational transitions of the amyloid peptides on aging. In the present data the conformational transitions that occur during amyloid formation from a random coil to β-sheet, sometimes contains intermediate structures with helical or mixture of other conformations. Data on CD in presence of osmolytes show their influence on the aggregation of the amyloid peptides. This data can be useful for developing fibrilization inhibitor or promotor/accelerator for the amyloid peptides/proteins. The osmolytes that stabilize the protein/peptide conformation can be a potential candidate against protein conformational diseases [1], [2], [3].

Data

The data presented here contain CD spectra of short peptide domains of Amyloid β-protein (Aβ) (Fig. 1, Fig. 2, Fig. 3), polyglutamine (polyQ) (Fig. 4, Fig. 5) and islet amyloid polypeptide (IAPP) (Fig. 6). Time dependent CD spectra of the peptides in presence of osmolytes have been presented. The CD data in absence of osmolytes presented here are peptide segments of Aβ and IAPP only. The data on polyQ without osmolytes have been published elsewhere [4]. IR spectra of some peptides without osmolytes have been shown in the supplemental data.
Fig. 1

CD spectra of Aβ peptides (A) Aβ(1–11), (B) Aβ(12–22), (C) Aβ(23–33) and (D) Aβ(34–42) in 10 mM phosphate buffer, pH 7.4.

Fig. 2

CD spectra of Aβ peptides (A) Aβ(1–11), (B) Aβ(12–22), (C) Aβ(23–33) and (D) Aβ(34–42) in 20%(v/v) glycerol.

Fig. 3

CD spectra of Aβ peptides (A) Aβ(1–11), (B) Aβ(12–22), (C) Aβ(23–33) and (D) Aβ(34–42) in 1 M TMAO.

Fig. 4

CD spectra of polyQ peptides (A) Q3, (B) Q6, (C) Q10, (D) Q14, (E) Q20 and (F) Q44 in 20%(v/v) glycerol.

Fig. 5

CD spectra of polyQ peptides (A) Q3, (B) Q6, (C) Q10, (D) Q14, (E) Q20 and (F) Q44 in 1 M TMAO.

Fig. 6

CD spectra of IAPP; hIAPP(20–29) (A, C and E) and rIAPP(20–31) (B, D and F), in 10 mM phosphate buffer pH 7.4 (A, B), in 20%(v/v) glycerol (C, D), and in 1 M TMAO (E, F).

Experimental design, materials and methods

Experimental design

The specific domains or segments of the amyloidogenic proteins used here were: Aβ peptide fragments, Aβ(1–11), Aβ(12–22), Aβ(23–33) and Aβ(34–42); polyQ peptides: Q3, Q6, Q10, Q14, Q20 and Q44; IAPP peptides: hIAPP(20–29) and rIAPP(20–31) (negative control). We used CD spectroscopy to monitor the conformational changes that occur during the transition to β-sheet conformation that indicate amyloid formation at different time points. As osmolytes are known to prevent aggregation or amyloid formation, we used the osmolytes glycerol and TMAO to monitor those conformational changes. The time points chosen to record CD spectra were 0 h, 24, 48, 72, 96 and 120 h.

Peptide synthesis

Aβ peptide fragments: Aβ(1–11), Aβ(12–22), Aβ(23–33) and Aβ(34–42), polyQ peptides: Q3, Q6, Q10, Q14, Q20 and Q44, IAPP peptides: hIAPP(20–29) and rIAPP(20–31), were chemically synthesized, purified, and characterized as described [4], [5], [6]. Briefly, peptides were synthesized by solid phase peptide synthesis method using Fmoc (9-fluorenylmethoxy carbonyl) strategy. The purity of the peptides was >95%, analyzed using reverse-phase high-performance liquid chromatography and the molecular weight was determined by MALDI-TOF mass spectroscopy.

Sample preparation

The peptides were disaggregated using TFE/HFIP procedure [7]. The peptides were dissolved in 10 mM phosphate buffer pH7.4 or osmolyte solutions; 20% (v/v) glycerol or 1 M trimethylamine-N-oxide (TMAO) for CD measurements. Freshly prepared peptide solutions at a concentration of 0.3 mg/mL were used for the experiments.

Circular dichroism spectroscopy

Spectra were acquired periodically during incubation of the peptides at 25 °C. The peptide solution was placed into a 0.1 cm path length quartz cuvette. Spectra were acquired using a Jasco Model J-715 spectropolarimeter (Jasco, Japan) from ≈190 to 260 nm at 0.2 nm resolution with a scan rate of 100 nm/min. Five scans were acquired and averaged for each sample. Raw data were manipulated by smoothing and subtraction of buffer spectra according to the manufacturer׳s instructions. The data is represented in mean residue molar ellipticity [θ] (deg cm2 dmol−1). For some samples, high photomultiplier voltage at low wavelength precluded data acquisition to wavelengths as low as 190 nm. The CD spectra of far-UV region (typically 190 to 240 nm) generally reflects the secondary structure content of the proteins and peptides [8]. The common secondary structure motifs such as the α-helix, β-pleated sheets, β-turns, and poly-L-proline II have very characteristic CD spectra [9]. A negative band near 218 nm and a positive band in the 195 to 200 nm region are characteristic of ß-sheet conformation. A negative band near 198 nm region is characteristic of random coil structure. α-helices are characterized by negative bands at 222 nm and 208 nm and a positive band between 190–195 nm.

Data processing

Data were processed and plotted using the graphical software “GraphPad Prism 6”.
Subject areaChemistry, Biology, Medicine
More specific subject areaBiophysical Chemistry
Type of dataSpectra, graph, figure
How data was acquiredCircular Dichroism (CD) spectroscopy (Jasco J-715 model spectropolarimeter), Infrared spectroscopy (Thermo Nicolet, AVATAR 320 Model)
Data formatAnalyzed data
Experimental factorsThe peptides were disaggregated using TFA/HFIP before starting the experiments. The peptides were dissolved and incubated in phosphate buffer or osmolyte solutions.
Experimental featuresSecondary structure of peptides was determined. Time dependent conformational changes were measured. Effect of osmolytes on the aggregation was monitored.
Data source locationChennai, India, and Stanford, USA
Data accessibilityThe data is with this article.
  8 in total

1.  Solubilization and disaggregation of polyglutamine peptides.

Authors:  S Chen; R Wetzel
Journal:  Protein Sci       Date:  2001-04       Impact factor: 6.725

2.  Conformational disease.

Authors:  R R Kopito; D Ron
Journal:  Nat Cell Biol       Date:  2000-11       Impact factor: 28.824

Review 3.  The use of circular dichroism in the investigation of protein structure and function.

Authors:  S M Kelly; N C Price
Journal:  Curr Protein Pept Sci       Date:  2000-12       Impact factor: 3.272

Review 4.  Mechanistic studies of the process of amyloid fibrils formation by the use of peptide fragments and analogues: implications for the design of fibrillization inhibitors.

Authors:  Ehud Gazit
Journal:  Curr Med Chem       Date:  2002-10       Impact factor: 4.530

5.  Self-assembly and sequence length dependence on nanofibrils of polyglutamine peptides.

Authors:  Mohammed Inayathullah; Aaron Tan; Rebecca Jeyaraj; James Lam; Nam-Joon Cho; Corey W Liu; Martin A C Manoukian; Keyoumars Ashkan; Morteza Mahmoudi; Jayakumar Rajadas
Journal:  Neuropeptides       Date:  2016-02-03       Impact factor: 3.286

Review 6.  How to study proteins by circular dichroism.

Authors:  Sharon M Kelly; Thomas J Jess; Nicholas C Price
Journal:  Biochim Biophys Acta       Date:  2005-08-10

7.  Conformational polymorphism and cellular toxicity of IAPP and beta AP domains.

Authors:  Maneesha E Andrews; N Mohammed Inayathullah; Rajadas Jayakumar; E J Padma Malar
Journal:  J Struct Biol       Date:  2009-05       Impact factor: 2.867

8.  Chemical chaperone and inhibitor discovery: potential treatments for protein conformational diseases.

Authors:  Jian-Hua Zhao; Hsuan-Liang Liu; Hsin-Yi Lin; Chih-Hung Huang; Hsu-Wei Fang; Shiao-Shing Chen; Yih Ho; Wei-Bor Tsai; Wen-Yih Chen
Journal:  Perspect Medicin Chem       Date:  2007-12-11
  8 in total
  2 in total

1.  Ameliorating amyloid aggregation through osmolytes as a probable therapeutic molecule against Alzheimer's disease and type 2 diabetes.

Authors:  Anchala Kumari; Pallavi Somvanshi; Abhinav Grover
Journal:  RSC Adv       Date:  2020-03-25       Impact factor: 4.036

Review 2.  Osmolytes: A Possible Therapeutic Molecule for Ameliorating the Neurodegeneration Caused by Protein Misfolding and Aggregation.

Authors:  Neetu Kushwah; Vishal Jain; Dhananjay Yadav
Journal:  Biomolecules       Date:  2020-01-13
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.